These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 12469151)
1. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis. Murata Y; Ogawa Y; Saibara T; Nishioka A; Takeuchi N; Kariya S; Onishi S; Yoshida S Oncol Rep; 2003; 10(1):97-100. PubMed ID: 12469151 [TBL] [Abstract][Full Text] [Related]
2. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933 [TBL] [Abstract][Full Text] [Related]
3. Tamoxifen-induced transient multifocal hepatic fatty infiltration. Cai Q; Bensen M; Greene R; Kirchner J Am J Gastroenterol; 2000 Jan; 95(1):277-9. PubMed ID: 10638597 [TBL] [Abstract][Full Text] [Related]
4. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796 [TBL] [Abstract][Full Text] [Related]
5. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. Nishino M; Hayakawa K; Nakamura Y; Morimoto T; Mukaihara S AJR Am J Roentgenol; 2003 Jan; 180(1):129-34. PubMed ID: 12490491 [TBL] [Abstract][Full Text] [Related]
6. [Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen]. Dray X; Tainturier MH; De La Lande P; Marty O; Mallet L Gastroenterol Clin Biol; 2000 Nov; 24(11):1122-3. PubMed ID: 11139682 [TBL] [Abstract][Full Text] [Related]
7. Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate. Ogawa Y; Murata Y; Saibara T; Nishioka A; Kariya S; Yoshida S Oncol Rep; 2003; 10(5):1473-8. PubMed ID: 12883726 [TBL] [Abstract][Full Text] [Related]
8. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106 [TBL] [Abstract][Full Text] [Related]
10. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients. Ohnishi T; Ogawa Y; Saibara T; Nishioka A; Kariya S; Fukumoto M; Onishi S; Yoshida S Oncol Rep; 2005 Mar; 13(3):485-9. PubMed ID: 15706422 [TBL] [Abstract][Full Text] [Related]
11. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer. Akhondi-Meybodi M; Mortazavy-Zadah MR; Hashemian Z; Moaiedi M Arab J Gastroenterol; 2011 Mar; 12(1):34-6. PubMed ID: 21429453 [TBL] [Abstract][Full Text] [Related]
12. Invasive and non-invasive investigations for tamoxifen-induced non-alcoholic steatohepatitis (NASH): the benefit of computed tomography scan guided liver biopsy. Ahmed MH; Osman KA; Osman MM Pathology; 2006 Jun; 38(3):270-1. PubMed ID: 16753757 [No Abstract] [Full Text] [Related]
13. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. Nemoto Y; Saibara T; Ogawa Y; Zhang T; Xu N; Ono M; Akisawa N; Iwasaki S; Maeda T; Onishi S Intern Med; 2002 May; 41(5):345-50. PubMed ID: 12058881 [TBL] [Abstract][Full Text] [Related]
14. Tamoxifen-induced fatty liver in patients with breast cancer. Ogawa Y; Murata Y; Nishioka A; Inomata T; Yoshida S Lancet; 1998 Mar; 351(9104):725. PubMed ID: 9504521 [No Abstract] [Full Text] [Related]
15. Fatty liver and drugs. Grieco A; Forgione A; Miele L; Vero V; Greco AV; Gasbarrini A; Gasbarrini G Eur Rev Med Pharmacol Sci; 2005; 9(5):261-3. PubMed ID: 16237810 [TBL] [Abstract][Full Text] [Related]
16. Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist. Ahmed MH; Osman KA Breast Cancer Res Treat; 2006 May; 97(2):223-4. PubMed ID: 16322887 [No Abstract] [Full Text] [Related]